title: Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.
abstract: The natural-killer(NK)-cell-mediated cytotoxicity to syngeneic tumor cells can be augmented by in vivo priming and subsequent in vitro challenge with the streptococcal preparation OK432. Supernatants of cocultures of spleen cells with OK432 contained interleukin-2 (IL-2) and interferon (IFN), mainly IFN-gamma. As the anti-(mouse IFN-gamma) monoclonal antibody but not anti-(mouse IFN-alpha) antibody inhibited the induction of activated NK cells with OK432, the IFN-gamma participated in this response. The enhancement of NK cell activity and production of IL-2 were partially inhibited by the pretreatment of spleen cells with mitomycin C or irradiation, and were completely abolished by pretreatment with actinomycin D. The IL-2 activity after treatment with various metabolic inhibitors ran parallel to the NK activity in a system augmented with OK432. The activity of incubated spleen cells with IL-2 receptors was increased by OK432 treatment, and the NK cell and IFN activities of supernatants were also abrogated by the treatment with anti-(mouse IL-2 receptor) monoclonal antibody, to block the interaction between IL-2 and these receptors of effector cells. The panning method clarified that the incubated spleen cells with IL-2 receptors are responsible for the production of IFN-gamma. These results suggest that IL-2 plays a major role in inducing the activated NK cells from murine spleen cells primed in vivo and subsequently challenged in vitro with OK432, by the production of IFN-gamma.
authors.affiliation: Department of Gastroenterological Surgery, Wakayama Medical College, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Yamaue
authors.forename: H
authors.initials: H
authors.lastname: Tanimura
authors.forename: M
authors.initials: M
authors.lastname: Iwahashi
authors.forename: M
authors.initials: M
authors.lastname: Tani
authors.forename: T
authors.initials: T
authors.lastname: Tsunoda
authors.forename: K
authors.initials: K
authors.lastname: Tabuse
authors.forename: K
authors.initials: K
authors.lastname: Kuribayashi
authors.forename: K
authors.initials: K
authors.lastname: Saito
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000502:physiology; D001688:Biological Products / Q000494:pharmacology*; D002478:Cells, Cultured; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology / Q000502:physiology*; D007376:Interleukin-2 / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D010844:Picibanil / Q000494:pharmacology*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D015375:Receptors, Interleukin-2 / Q000276:immunology; D013154:Spleen
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D001688:Biological Products; D007376:Interleukin-2; D011500:Protein Synthesis Inhibitors; D015375:Receptors, Interleukin-2; D010844:Picibanil; D007371:Interferon-gamma